Clinical Trials Logo

Urinary Retention clinical trials

View clinical trials related to Urinary Retention.

Filter by:

NCT ID: NCT01568918 Terminated - Clinical trials for Postoperative Urinary Retention

Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Start date: May 2012
Phase: Phase 3
Study type: Interventional

Postoperative urinary retention is a frequent complication of spinal surgeries and impacts a large portion of this population which results in increased morbidity as a result of increased number of catheterizations, urinary tract infections (UTIs) and prolonged hospital stays. With the addition of Tamsulosin, the investigators would anticipate a reduction in the incidence and duration of postoperative urinary retention and therefore a reduction in morbidity related to treatment of urinary retention as well as shortened hospital stays.

NCT ID: NCT01462656 Terminated - Epilepsy Clinical Trials

Risk of Urinary Retention With Retigabine

Start date: February 2011
Phase: N/A
Study type: Observational

A prospective cohort study of antiepileptic drug (AED) polytherapy-treated epilepsy patients within the HealthCore Integrated Research Database (HIRD) will be conducted. Following the launch of Ezogabine (EZG), patients initiating a new AED polytherapy regimen will be followed until the earliest of an episode of urinary retention (UR), change in their AED regimen, end of follow-up, or end of study (when the specified sample size of EZG AED polytherapy users has been attained). After the end of study, the incidence of UR during exposures to EZG and non-EZG AED polytherapies will be compared. Polytherapy will be defined as treatment regimen containing at least two different AEDs. A prospective cohort study of patients who receive EZG under circumstances not indicated in the product label within the HIRD will also be conducted. Following the launch of EZG, epilepsy patients initiating AED monotherapy with EZG as well as non-epilepsy patients initiating EZG for another disease will be followed until the earliest of an episode of UR, change in their AED regimen (if applicable), end of follow-up, or end of study. The incidence of UR during exposure to EZG under circumstances not indicated in the product label will be described. A descriptive analysis of the patients will also be included. To meet the other secondary objective, non-EZG AED monotherapy users will be identified in the prospective cohort and incidence of UR will be calculated to determine if there is a difference in UR risk between monotherapy and polytherapy AED use.

NCT ID: NCT00804557 Terminated - Urinary Retention Clinical Trials

Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization

Start date: October 2008
Phase: N/A
Study type: Observational

To evaluate the ease of use and comfort of a new urinary catheter, the Uro-Ease, as used in the Clean Intermittent Catheterization (CIC)process.

NCT ID: NCT00563654 Terminated - Clinical trials for Prostatic Hyperplasia

Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Start date: October 2005
Phase: N/A
Study type: Interventional

The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

NCT ID: NCT00563485 Terminated - Clinical trials for Prostatic Hyperplasia

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Start date: October 2005
Phase: N/A
Study type: Interventional

The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

NCT ID: NCT00453908 Terminated - Urinary Retention Clinical Trials

Alfuzosin Versus Placebo in Acute Urinary Retention

ALF-RIK
Start date: May 2004
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization. Furthermore is investigated the safety of the medical treatment and self-catheterization.

NCT ID: NCT00441935 Terminated - Clinical trials for Urinary Incontinence

InterStim Prospective Database

Start date: April 2004
Phase: N/A
Study type: Observational

The study is to collect information from patient charts and patient questionnaires to evaluate the effects of nerve stimulation therapy on urinary dysfunction.

NCT ID: NCT00421421 Terminated - Clinical trials for Benign Prostatic Hyperplasia

Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in patients who receive a 6 month treatment of dutasteride (0.5mg once daily) following a single episode of AUR followed by successful Trial Without Catheter compared with placebo.

NCT ID: NCT00225966 Terminated - Urinary Retention Clinical Trials

Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control

Start date: August 2004
Phase: N/A
Study type: Interventional

The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.